Silas Inman

BNT162b1, a SARS-CoV-2 vaccine candidate, elicited promising early signs of immune activity in a placebo-controlled phase 1/2 study.

FDA grants emergency use authorization for a new rapid point-of-care molecular SARS-CoV-2 diagnostic.

FDA grants emergency use authorization for Cepheid's point-of-care COVID-19 diagnostic, Xpert Xpress SARS-CoV-2.

"We're going to have to figure out what our American approach is to this to and how we're going to take more aggressive mitigation steps," Scott Gottlieb, MD, said in his keynote address.

The FDA approves meropenem-vaborbactam (Vabomere) for the treatment of adult patients with complicated urinary tract infections, including those with pyelonephritis.

Republicans in the House of Representatives have proposed a replacement bill for the Affordable Care Act (ACA) labeled the American Health Care Act.